Cic Biogune
CIC bioGUNE is a non-profit biosciences research institute in Derio, Spain, operating NMR, electron microscopy, proteomics, metabolomics, and animal facility platforms. It serves academic, hospital, and pharmaceutical R&D customers through service contracts and collaborative research, and translates discoveries into spin-off companies.
- Company typePrivate
- Founded2003
- HeadquartersDerio, Spain
- Headcount101–250
- GTM typeB2B
- OfferingServices
What Cic Biogune does
CIC bioGUNE is a non-profit research association (Asociación) founded in 2003 and headquartered in Derio, Basque Country, Spain, operating at the interface of chemistry, structural and molecular biology, and biomedicine. It functions as a translational biosciences research institute, generating knowledge, IP, and spin-off companies rather than commercial products, and serves academic, hospital, and pharmaceutical R&D customers through service platforms and collaborative research. Core technology infrastructure includes a 600 MHz NMR spectroscopy platform (operated under a Bruker technology partnership), electron microscopy, proteomics, metabolomics (including proprietary 31P-NMR methodology), genome analysis, and an animal facility accredited by AAALAC. The institute holds Severo Ochoa Centre of Excellence accreditation (renewed 2023-2027), is a member of the Basque Research & Technology Alliance (BRTA), and maintains ISO 9001, ISO 13485, and ISO 56001 certifications.
The institute's outputs include peer-reviewed research, proprietary software (e-COMETA, ISO 13485-certified for newborn congenital metabolic error diagnosis), and spin-off companies including ATLAS Molecular Pharma (pharmacological chaperones for rare diseases, with Orphan Drug Designation) and Adaptam Therapeutics (cancer immunotherapies, founded 2023). The Scientific Advisory Board includes Nobel Laureate Richard Henderson. Revenue mechanics are not publicly disclosed; the institute appears to operate on a mix of competitive public grants (Spanish national, Basque regional, EU), service contracts (NMR, EM, proteomics, metabolomics, animal facility), and equity/value capture from spin-offs. Customer segments include Spanish hospital networks and international academic collaborators (Imperial College, Cambridge, Lübeck, Vanderbilt, Newcastle, Cedars-Sinai, Murdoch, University of Florida, Washington University, Milan).
Cic Biogune firmographics
Firmographics- Name
- Cic Biogune
- Legal name
- ASOCIACIÓN CENTRO DE INVESTIGACIÓN COOPERATIVA EN BIOCIENCIAS – CIC bioGUNE
- Website
- https://cicbiogune.es
- Company type
- Private
- Founded year
- 2003
- Operating status
- Operating
- Headcount range
- 101–250 employees
- Short description
- CIC bioGUNE is a non-profit biosciences research institute in Derio, Spain, operating NMR, electron microscopy, proteomics, metabolomics, and animal facility platforms. It serves academic, hospital, and pharmaceutical R&D customers through service contracts and collaborative research, and translates discoveries into spin-off companies.
- Ownership category
- akta.pro rank
Cic Biogune industry classification
Industry- Product category
- Bioscience Research Services
- NAICS
- Other Scientific and Technical Consulting Services (54169)
- SIC
- Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Clinical Research & Trial Central Laboratories (HLAFAMAL)
Keywords
Where Cic Biogune is headquartered
LocationHeadquarters
- HQ city
- Derio
- HQ country
- Spain
- HQ region
- Europe
Offices2 records
Markets served
Cic Biogune business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations, Infrastructure
Distribution channels1 record
Marketing channels3 records
Cic Biogune product offering
Product offeringCore offering
CIC bioGUNE is a non-profit bioscience research center that provides fee-based analytical and research services through six core technology platforms: Electron Microscopy and Crystallography, Nuclear Magnetic Resonance (NMR), Metabolomics, Proteomics, Genome Analysis, and an Animal Facility. It also develops certified medical software (e-COMETA) and licenses proprietary therapeutics such as pharmacological chaperones for rare diseases.
Product overview
CIC bioGUNE is a Center for Cooperative Research in Biosciences providing research services through six core technology platforms (Electron Microscopy and Crystallography, NMR, Proteomics, Metabolomics, Genome Analysis, and Animal Facility). The center also develops and manufactures the e-COMETA software for newborn congenital metabolic error diagnosis, and has spun off companies including ATLAS Molecular Pharma (pharmacological chaperone therapies) and Adaptam Therapeutics (cancer immunotherapies).
Differentiator
Problem solved
Functional benefit
Products and services
- e-COMETA software ISO 13485:2016-certified software designed, developed, and manufactured to aid in the diagnosis of newborn congenital metabolic errors using Nuclear Magnetic Resonance (NMR) analysis. Supports early detection of congenital metabolic disorders in the earliest stages of life. Built by the Precision Medicine and Metabolism Lab led by Óscar Millet.
- Technology Platforms — Electron Microscopy, NMR, Proteomics, Metabolomics, Genome Analysis Six core technology platforms providing fee-based analytical research services to external academic institutions, hospitals, and industry clients. Includes: Electron Microscopy and Crystallography (transmission electron microscopes for sub-nm 3D reconstruction); NMR (IVDr 600 MHz spectrometers); Proteomics; Metabolomics (population-scale profiling of 10,000+ individuals); Genome Analysis; and an Animal Facility. Services governed by General Terms and Conditions of Sale.
- Animal Facility AAALAC International-accredited animal research facility supporting in vivo studies for the center's research programs, providing humane care and use of animals in research.
- Pharmacological Chaperone for Congenital Erythropoietic Porphyria Out-licensable therapeutic compound identified by the Precision Medicine and Metabolism Lab for treating congenital erythropoietic porphyria, a disorder of the heme biosynthetic pathway. Has received Orphan Drug Designation status. Further developed commercially through the spin-off ATLAS Molecular Pharma.
Companies that use Cic Biogune
Customer profileSegments1 record
Ideal customer profiles2 records
Cic Biogune technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature5 records
Cic Biogune partnerships and signals
Strategic signalPartnerships
14 partnerships are on record, tiered core and major.
- Adaptam TherapeuticscoreAdaptam Therapeutics was founded in 2023 as a spin-out from CIC bioGUNE. The company focuses on developing cancer immunotherapies targeting immunosuppressive myeloid cells, with particular emphasis on glyco-immune checkpoint modulation for solid tumors. The spin-off is advancing antibody-based therapies including ADCs and bispecific antibodies.
- ATLAS Molecular PharmacoreSpin-off company created from CIC bioGUNE's Precision Medicine and Metabolism Lab. The company is developing pharmacological chaperones for rare diseases, including a treatment for congenital erythropoietic porphyria that has received Orphan Drug Designation status.
- Murdoch University (Jeremy Nicholson & Julien Wist)majorInternational research collaboration in metabolomics and NMR spectroscopy applications for precision medicine.
- Lübeck University (Ulrich Guenther)majorResearch collaboration in NMR spectroscopy and metabolomics methodologies.
- Vanderbilt University (Simon Mallal & Markus Voehler)majorInternational collaboration in NMR spectroscopy and metabolomics research.
- Imperial College London (Gary Frost & Elaine Holmes)majorCollaboration in metabolomics and metabolic research for precision medicine applications.
- Bruker (Manfred Spraul & Harmut Schaeffer)majorTechnology partnership with Bruker for NMR spectroscopy equipment and methodologies, including IVDr 600 MHz spectrometers.
- Newcastle University (Quentin Anstee)majorCollaboration in liver disease research and metabolomics applications.
- Cedars Sinai (Shelly Lu & Mazen Noureddin)majorInternational research collaboration in liver disease and metabolism research.
- University of Florida (Kenneth Cusi)majorResearch collaboration in metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolomics.
- Washington University (Nicholas Davidson)majorInternational collaboration in liver metabolism and metabolic disease research.
- Cambridge University (Toni Vidal)majorResearch collaboration in metabolic research and precision medicine.
- University of Milan (Luca Valenti)majorCollaboration in metabolic liver disease research.
- Hospital Network CollaborationsmajorCollaborations with multiple Spanish hospitals including Hospital Clínico San Carlos, Hospital de Basurto, Hospital de Galdakao, Hospital de Txagorritxu, Hospital Príncipe de Asturias, and Hospital Valme for clinical research translation.
Scale indicators3 records
Recent moves7 records
Expansion highlights5 records
Cic Biogune competitors and assessment
Company assessmentDirect peers
- Centre for Genomic Regulation (CRG): Barcelona-based international life sciences research institute with genome analysis, proteomics, and advanced microscopy platforms. Direct peer given overlapping omics platforms, biomedical research mandate, and similar public-grant funding structure in the Spanish research ecosystem.
- CIC nanoGUNE: Sister Basque cooperative research center also under BRTA, focused on nanoscience and nanotechnology with electron microscopy capabilities. Direct peer given shared institutional structure, BRTA membership, and electron microscopy platform overlap.
- Helmholtz Munich: German research center with internationally recognized metabolomics and NMR capabilities for population-level health research. Direct peer given strong overlap with CIC bioGUNE's metabolomics, NMR platform, and biomarker discovery mandate.
- Max Planck Institute for Biophysical Chemistry: Leading German research institute with deep NMR spectroscopy and structural biology expertise (Christian Griesinger, SAB member at CIC bioGUNE). Direct peer for NMR methodology development and biophysical chemistry research.
- CIC bioMAGUNE: Sister Basque Country cooperative research center also operating under the BRTA umbrella, specializing in molecular imaging and NMR-related biomedical research. Directly comparable as a peer non-profit research institute in the same regional science and technology park ecosystem with overlapping NMR and structural biology capabilities.
- IRB Barcelona: Spanish non-profit biomedical research institute conducting frontier research in molecular and cellular biology, with similar size, talent composition, and public grant funding model. Direct peer given comparable research mandate, technology platform strategy, and Severo Ochoa-tier status in Spain.
- Centro Nacional de Investigaciones Oncológicas (CNIO): Spain's leading national cancer research center, also a peer on the CIC bioGUNE Scientific Advisory Board (Dr. Marisol Soengas). Direct peer in life sciences research with comparable Severo Ochoa-tier recognition and a strong spin-off / industry translation track record.
Broad incumbents
- European Molecular Biology Laboratory (EMBL): Pan-European intergovernmental life sciences research organization with multi-site operations and broader scope covering structural biology, genomics, and chemical biology. Larger and broader incumbent operating in adjacent scientific domains with overlapping technology platforms.
- Francis Crick Institute: Large UK biomedical discovery institute with broad research programs across cancer, immunology, neuroscience, and structural biology. Larger incumbent peer given comparable research mandate, technology platform focus, and public-grant-backed operating model.
Emerging players
- Institute of Molecular Biology (IMB) Mainz: German research institute focused on epigenetics, DNA repair, and quantitative proteomics with advanced genomics and proteomics platforms. Emerging player peer with overlapping life science research mandate and technology platform focus.
Market position
Strengths5 records
Weaknesses4 records
Competitive moat5 records
Key risks5 records
Key highlights6 records
Customer concentration
Cic Biogune social profiles
Digital presenceCic Biogune compliance and trust
Trust signalCompliance4 records
Cic Biogune financial estimates
Financial estimateRevenue estimate
Valuation estimate
Cic Biogune leadership team
Management profileNumber of profiles
Profiles2 records
Cic Biogune funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Cic Biogune M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Cic Biogune
What does Cic Biogune do?
CIC bioGUNE is a non-profit bioscience research center that provides fee-based analytical and research services through six core technology platforms: Electron Microscopy and Crystallography, Nuclear Magnetic Resonance (NMR), Metabolomics, Proteomics, Genome Analysis, and an Animal Facility. It also develops certified medical software (e-COMETA) and licenses proprietary therapeutics such as pharmacological chaperones for rare diseases.
Is Cic Biogune a public or private company?
Cic Biogune is a private company. It is classified as nonprofit foundation owned and is currently operating.
When was Cic Biogune founded?
Cic Biogune was founded in 2003. It employs 101 to 250 people.
Where is Cic Biogune based?
Cic Biogune is headquartered in Derio, Spain, in the Europe region.
Who are Cic Biogune's main competitors?
Direct peers on record are Centre for Genomic Regulation (CRG), CIC nanoGUNE, Helmholtz Munich, Max Planck Institute for Biophysical Chemistry, CIC bioMAGUNE, IRB Barcelona and Centro Nacional de Investigaciones Oncológicas (CNIO). Broad incumbents are European Molecular Biology Laboratory (EMBL) and Francis Crick Institute. Institute of Molecular Biology (IMB) Mainz is listed as an emerging player.
Does Cic Biogune have an API?
No public API is recorded for Cic Biogune.
What industry is Cic Biogune in?
Cic Biogune's product category is Bioscience Research Services. Its primary akta.pro industry code is HLAFAMAL, Clinical Research & Trial Central Laboratories. Its NAICS code is 54169 and its SIC code is 8731.